UroGen Pharma Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
URGN Nasdaq 2836 www.urogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for UroGen Pharma Ltd.

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Mar 12th, 2025 7:00 pm
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates - Mar 10th, 2025 1:10 pm
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Mar 10th, 2025 12:00 pm
Exploring High Growth Tech Stocks in the US Market - Mar 7th, 2025 5:08 pm
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 7th, 2025 1:00 pm
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - Feb 27th, 2025 1:00 pm
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Feb 25th, 2025 5:30 pm
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - Feb 24th, 2025 9:00 pm
UroGen acquires IconOVir’s oncolytic virus assets - Feb 21st, 2025 3:53 pm
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Feb 20th, 2025 1:00 pm
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Feb 14th, 2025 7:30 pm
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology - Feb 12th, 2025 1:00 pm
UroGen Pharma to Present at Upcoming Investor Conferences - Jan 30th, 2025 1:00 pm
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Jan 22nd, 2025 1:00 pm
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Jan 15th, 2025 1:00 pm
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Dec 31st, 2024 12:06 pm
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® - Dec 5th, 2024 8:30 pm
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Dec 5th, 2024 8:15 pm
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade - Dec 2nd, 2024 10:44 pm
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - Dec 2nd, 2024 1:00 pm